CEP-1347 Cephalon

IDrugs

Volumn 6, Issue 4, 2003, Pages 377-383

  Mucke, Herman A M ^a  

^a HM Pharma Consultancy   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CEP 11004; CEP 1347; INDOLOCARBAZOLECHOLINE ACETYLTRANSFERASE INHIBITOR; K 252A; LEVODOPA; PLACEBO; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HEADACHE; HUMAN; NAUSEA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; REVIEW; STRUCTURE ACTIVITY RELATION; VERTIGO;

ANIMALS; CARBAZOLES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; INDOLES; NEUROPROTECTIVE AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038368156     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. 188282 Potent and selective neutrophic derivatives of K252a. Mallamo JP, Kaeur JC, Hudkins RC, Rotella DP, Glicksman MA, Saporito M, Carswell S, Haun F, KnightJr E, Neff NT, Vaught JL et al Symp Med Chem Approaches Alzheimers Dis 1995 2 August 28-30
2. 257561 Neurotrophic 3,9-bis[(alkylthio)methyl]- and -bis(alkoxymethyl)-K-252a derivatives. Kaneko M, Saito Y, Saito H, Matsumoto T, Matsuda Y, Vaught JL, Dionne CA, Angeles TS, Glicksman MA, Neff NT, Rotella DP et al J Med Chem 1997 40 12 1863-1869
3. 280426 Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. Maroney AC, Glicksman MA, Basma AN, Walton KM, Knight EJr, Murphy CA, Bartlett BA, Finn JP, Angeles T, Matsuda Y, Neff NT, Dionne CA J Neurosci 1998 18 1 104-111
4. 292606 Chronic sparing of delayed alternation performance and choline acetyltransferase activity by CEP-1347/KT-7515 in rats with lesions of nucleus basalis magnocellularis. DiCamillo AM, Neff NT, Carswell S, Haun FA Neuroscience 1998 86 2 473-483
5. 293070 Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis. Saporito MS, Brown ER, Carswell S, DiCamillo AM, Miller MS, Murakata C, Neff NT, Vaught JL, Haun FA Neuroscience 1998 86 2 461-472
6. 311880 British Pharmacological Society - Winter Meeting, Brighton, UK. Chazot P IDDB Meeting Report 1999 January 06-08
7. 318123 Cephalon's JNK blocker in Parkinson's disease passes test in animal model. Emerging Pharmaceuticals 1999 8 3 12
8. 321708 Kyowa Hakko Kogyo's pharmaceutical R&D. Kyowa Hakko Kogya Co Ltd Company World Wide Website 1999 April 19
9. 326524 Cephalon announces R&D collaboration with Lundbeck to develop products neurodegenerative diseases. Cephalon Inc Press Release 1999 June 01
10. 326869 Effects of c-Jun N-terminal kinase (JNK) inhibition on cerulein-induced pancreatis in rats. Wagner A, Mazzuchelli L, Miller M, Cameratto AM Gastroenterology 1999 May 16-19 Abs 1781
11. 333660 Cephalon and Lundbeck initiate clinical program with CEP-1347 for neurodegenerative diseases. Cephalon Inc Press Release 1999 July 22
12. 335178 K-252a, a potent inhibitor of protein kinase C from microbial origin. Kase H, Iwahashi K, Matsuda Y J Antibiot (Tokyo) 1986 39 8 1059-1065
13. 337009 Neuronal Apoptosis - ISN Satellite Symposium, Tubingen, Germany. Perry G IDDB Meeting Report 1999 August 05-07
14. 344981 New compound, CEP-1347, demonstrates potential for halting the progression of Parkinson's disease. Positive results seen in Parkinson's disease models. Cephalon Inc Press Release 1999 October 27
15. 345213 The neuroprotective effects of CEP-1347 in a primate model of MPTP-induced chronic progressive parkinsonism. Konitsiotis S, Saporito MS, Flood DG, Hyland K, Miller M, Lin YG, Arnold LA, LePoole K, Bibbiani F, Blanchet PJ, Chase TN Abstr Soc Neurosci 1999 25 Pt 2 Abs 639.4
16. 345793 CEP-1347, an inhibitor in the JNK pathway, protects against in vitro toxicity of malonate. Eberhardt O, Saporito MS, Topka H, Schulz JB Abstr Soc Neurosci 1999 25 Pt 1 Abs 332.6
17. 349382 CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. Maroney AC, Finn JP, Bozyczko-Coyne D, O'Kane TM, Neff NT, Tolkovsky AM, Park DS, Yan CY, Troy CM, Greene LA J Neurochem 1999 73 5 1901-1912
18. 349385 CEP-1347/KT-7515, an inhibitor of c-Jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. Saporito MS, Brown EM, Miller MS, Carswell S J Pharmacol Exp Ther 1999 288 2 421-427
19. 349387 CEP-1347/KT7515, a JNK pathway inhibitor, supports the in vitro survival of chick embryonic neurons. Borasio GD, Horstmann S, Anneser JM, Neff NT, Glicksman MA Neuroreport 1998 9 7 1435-1439
20. 349390 CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo. Glicksman MA, Chiu AY, Dionne CA, Harty M, Kaneko M, Murakata C, Oppenheim RW, Prevette D, Sengelaub DR, Vaught JL, Neff NT J Neurobiol 1998 35 4 361-370
21. 363997 CEP-1347/KT7515 inhibits gp120IIIB/CD4-induced apoptosis in a rat hippocampal and purkinje neurons. Bodner A, Miller RJ Clin Pharmacol Ther 67 2 PII-54
22. 372240 Drug development pipeline: CEP-1347. Cephalon Inc Company Communication 2000 June 14
23. 377448 K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Kase H, Iwahashi K, Nakanishi S, Matsuda Y, Yamada K, Takahashi M, Murakata C, Sato A, Kaneko M Biochem Biophys Res Commun 1987 142 2 1863-1869
24. 377450 Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. Pirvola U, Xing-Qun L, Virkkala J, Saarma M, Murakata C, Camoratto AM, Walton KM, Ylikoski J J Neurosci 2000 20 1 43-50
25. 2 terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostrial neurons in vivo. Saporito MS, Thomas BA, Scott RW Abstr Soc Neurosci 2000 26 1 Abs 10.6
26. 388519 CEP-1347/KT7515 rescues rat dorsal root ganglia from gp120IIIB-induced apoptosis. Bodner A, Oh SB, Tran P, Miller RJ Abstr Soc Neurosci 2000 26 2 Abs 633.3
27. 396408 Lundbeck pipeline. H Lundbeck A/S Company World Wide Website 2001 January 19
28. 397897 Drug development pipeline: [Sertindole, NC-531, Alzheimer's treatment with Gerolymatos, TV-1203, Almotriptan, CEP-1347, zonisamide]. H Lundbeck A/S Company Communication 2001 February 01
29. 406643 CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Aβ-induced cortical neuron apoptosis. Bozyczko-Coyn D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, Scott RW J Neurochem 2001 77 3 849-863
30. 406684 β-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, Greene LA J Neurochem 2001 77 1 157-164
31. 413670 Coming 4 to 5 years to be turning-point for globalization: Dr Suzuki of Kyowa Hakko. Pharma Japan 2001 1751 June 25 1-3
32. 418144 Neurodegenerative Drug Discovery and Development - New Directions, London, UK. Urbanics R IDDB Meeting Report 2001 July 18-19
33. 428033 Inhibition of nociceptive C-fiber reflex by CEP-1347: Spinal site of action. Grnuet JA, Fiocchi EM, Miller MS Abstr Soc Neurosci 2001 27 2 Abs 615.10
34. 428035 CEP-1347, an inhibitor of the c-Jun N-terminal kinase pathway has antiociceptive activity in phase II of the rat formalin model. Clas DM, Aimone LD, Fiocchi E, Miller MS Abstr Soc Neurosci 2001 27 2 Abs 615.8
35. 428819 CEP-1347 improves the survival of grafted dopaminergic neurons. Vaudano E, Kaminski G, Bisgaard-Boll J, Lesit M, Sager TN, Petersen K Abstr Soc Neurosci 2001 27 1 197.8
36. 429318 Protein Kinases in Drug Discovery & Development, Newark, NJ, USA. Hadari Y IDDB Meeting Report 2001 October 15-16
37. 429353 Cephalon reports that data show that CEP-1347 increased success of brain cell transplantation in models of Parkinson's disease. Cephalon Inc Press Release 2001 November 14
38. 434952 Mixed lineage kinase activity of indolocarbazole analogues. Murakata C, Kaneko M, Gessner G, Sangeles TS, Ator MA, O'Kane TM, McKenna BA, Thomas BA, Mathiasen JR, Saporito MS, Bozyczko-Coyne D, Hudkins RL Bioorg Med Chem Lett 2002 12 2 147-150
39. 443544 Product and development pipeline. Cephalon Inc Company World Wide Website 2002 March 15
40. 459861 Cephalon and H Lundbeck initiate clinical trial in patients with early stage Parkinson's disease. Cephalon Inc Press Release 2002 August 01
41. 471675 Parkinson's Disease and Movement Disorders - Seventh International Congress (Part I), 10-14 November 2002, Miami, FL, USA. O'Neill MJ IDDB Meeting Report 2002 November 10-14
42. 471855 Parkinson's Disease and Movement Disorders - Seventh International Congress (Part II), Miami, FL, USA. Anonymous IDDB Meeting Report 2002 November 10-14
43. 475909 Mixed lineage kinase 3 mediates gp120IIIB-induced neurotoxicity. Bodner A, Maroney AC, Finn JP, Ghadge G, Roos R, Miller J J Neurochem 2002 82 6 1424-1434
44. 476395 The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Nheu TV, He H, Hirokawa Y, Tamaki K, Florin L, Schmitz ML, Suzuki-Takahashi I, Jonssen RN, Burgess AW, Nishimura S Cancer J 2002 8 4 328-336
45. 476402 Inhibition of the c-Jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. Harris CA, Deshmukh M, Tsui Pierchala B, Maroney AC, Johnson Jr EM J Neurosci 2002 22 1 103-113
46. 476406 Blockade of c-Jun N-terminal kinase pathway attenuates gentamicin-induced cochlear and vestibular hair cell death. Ylikoski J, Xing-Qun L, Virkkala J, Pirvola U Hear Res 2002 166 1-2 33-43
47. 476411 CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. Maroney AC, Finn JP, Connors TJ, Durkin JT, Angeles T, Gessner G, Xu Z, Meyer SL, Savage MJ, Greene LA J Biol Chem 2001 276 27 25302-25308
48. 476412 The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Xu X, Maroney AC, Dobrzanski P, Kukekov NV, Greene LA Mol Cell Biol 2001 21 14 4713-4724
49. 476431 Arsenic induces apoptosis in rat cerebellar neurons via activation of JNK3 and p38 MAP kinases. Namgung U, Xia Z Toxicol Appl Pharmacol 2001 174 2 130-138
50. 2-terminal kinase regulate RANTES production by influenza virus-infected human bronchial epithelial cells. Kujime K, Hashimoto S, Gon Y, Shimizu K, Horie T J Immunol 2000 164 6 3222-3228
51. 478593 Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Saporito MS, Hudkins RL, Maroney AC Prog Med Chem 2002 40 23-62 A review of the history of CEP-1347 (and other analogs of K-252a) and its preclinical data.
52. 478596 K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK. Roux PP, Dorval G, Boudreau M, Angers-Loustau A, Morris SJ, Makkerh J, Barker PA J Biol Chem 277 51 49473-49480 CEP-1347 has an additional MLK-independent mechanism that might be related to c-Src.
53. 478601 NRAGE, a p75 neurotrophin receptor-interacting protein, induces caspase activation and cell death through a JNK-dependent mitochondrial pathway. Salehi AH, Xanthoudakis S, Barker PA J Biol Chem 2002 277 50 48043-48050
54. 478606 CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Aβ-induced cortical neuron apoptosis. Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, Scott RW J Neurochem 2001 77 3 849-863
55. 478616 CEP-1347 inhibits caerulein-induced rat pancreatic JNK activation and ameliorates caerulein pancreatitis. Wagner A, Mazzuchelli L, Miller AM, Camoratto Am, Goke B Am J Physiol - Gastrointest Liver Physiol 2000 278 1 G165-G172
56. 478715 Protein kinase C inhibitors; Structure-activity relationships in K252c-related compounds. Fabre S, Prudhomme M, Rapp M Bioorg Med Chem 1993 1 3 193-196
57. 479632 Clinical trials in progress: PRECEPT: Parkinson Research Examination of CEP-1347 Trial. INTERNET SITE 2003 February 2003 http://www.parkinson-study-group.org/Clinical%20Trials%20in%20Progress.html